US Stock MarketDetailed Quotes

OLMA Olema Pharmaceuticals

Watchlist

7.300
-1.110-13.20%

Trading Dec 12 10:32 ET

538.79MMarket Cap-3.20P/E (TTM)

Olema Pharmaceuticals Stock Forum

104079172

Dec 10 08:28

Might Olema have a chance of being acquired?

$Olema Pharmaceuticals (OLMA.US)$
Olema set for an operatic debut at last | ApexOnco - Clinical Trials news and analysis

Jaguar8

Dec 10 06:26

NEWS

$Olema Pharmaceuticals (OLMA.US)$
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology announced updated clinical results for palazestrant combined with ribociclib in treating ER+/HER2- advanced or metastatic breast cancer. With a 12-month median follow-up, the study showed promising results with median progression-free survival (PFS) not yet reached. The 6-month PFS rate was 73% overall, wit...

Trytosaveabit

Dec 10 06:02

Update

$Olema Pharmaceuticals (OLMA.US)$ Reuters· 1 min ago
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium

Jaguar8

Dec 9 06:08

NEWS

$Olema Pharmaceuticals (OLMA.US)$
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Olema Pharmaceuticals (Nasdaq: OLMA) announced FDA clearance of its Investigational New Drug (IND) application for OP-3136, a novel small molecule that inhibits KAT6, an epigenetic target involved in breast and other cancers. The company plans to initiate a Phase 1 clinical trial in early 2025. OP-3136 has shown promising preclinical activity ...

Trytosaveabit

Dec 9 06:05

Update

$Olema Pharmaceuticals (OLMA.US)$ Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE

Trytosaveabit

Dec 2 06:04

Update

$Olema Pharmaceuticals (OLMA.US)$ Reuters· 3 mins ago
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement

Trytosaveabit

Nov 30 10:33

Eyes on! TB on hourly! Plus data release coming could help bring volume to help push this bullish formation!

$Olema Pharmaceuticals (OLMA.US)$ Olema Oncology to Present New Data Combining Palazestrant With Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024
Poster Details
Title:A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal gr...

Moomoo AI

Nov 25, 2023 06:49

Although the sale doesn't necessarily signify a negative view on the company's future, absence of insider buying could induce concerns. Other company risks should be considered when investing.

President Sean Bohen Sold A Bunch Of Shares In Olema Pharmaceuticals

Moomoo AI

Oct 17, 2023 06:06

Mr. Garland's expertise in biopharma is predicted to boost late-stage development of Olema's lead product. This could solidify the company's influence in shaping next-gen therapies for women's cancers.

Press Release: Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Weight-loss drugmakers report strong earnings: Boon or bane?

Trytosaveabit

Oct 12, 2023 06:17

NEWS!

$Olema Pharmaceuticals (OLMA.US)$ Olema Pharmaceuticals Announced New Preclinical Data Regarding The Discovery Of Novel Compounds Targeting KAT6, An Epigenetic Target That Is Dysregulated In Breast And Other Cancers

No comment yet

Heat List

Overall

No Data